

# Establishment of leading compounds to overcome tumor heterogeneity and anticancer drug resistance of pancreatic cancer and liver cancer by using oncolytic adenovirus/mesenchymal stem cell complex capable of both enhanced tumor targeting and virus replication

Yonsei University



ONCOLOGY	Lead
Product Type	Oncolytic virus-infected engineered mesenchymal stem cell
Indication	Solid tumors[Primary :Pancreatic cancer (Gemcitabine resistance), Secondary : Liver cancer (Sorafenib resistance) and Lung
Target	Every solid tumors
MoA(Mechanism of Action)	Targeting solid tumor and loading TGF- $\beta$ , HSP27 – the tumor-suppressing MOAs of each factor's downregulation are complementary, and the downregulation of both maximizes tumor response rate.
Competitiveness	Immune checkpoint inhibitor, CAR-T cell
Development Stage	Lead
Route of Administration	Intravenous injection